AnaptysBio, Inc. (NASDAQ:ANAB) Shares Acquired by JPMorgan Chase & Co.

JPMorgan Chase & Co. boosted its position in AnaptysBio, Inc. (NASDAQ:ANAB) by 191.4% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 33,744 shares of the biotechnology company’s stock after purchasing an additional 22,164 shares during the period. JPMorgan Chase & Co.’s holdings in AnaptysBio were worth $1,130,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Values First Advisors Inc. acquired a new stake in shares of AnaptysBio in the third quarter valued at $49,000. nVerses Capital LLC raised its position in AnaptysBio by 700.0% in the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock worth $54,000 after acquiring an additional 1,400 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in AnaptysBio by 81.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock valued at $195,000 after acquiring an additional 2,600 shares during the last quarter. Point72 DIFC Ltd boosted its position in shares of AnaptysBio by 680.5% during the 3rd quarter. Point72 DIFC Ltd now owns 6,127 shares of the biotechnology company’s stock valued at $205,000 after purchasing an additional 5,342 shares in the last quarter. Finally, Intech Investment Management LLC acquired a new position in shares of AnaptysBio in the 3rd quarter worth approximately $229,000.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Truist Financial reduced their target price on shares of AnaptysBio from $30.00 to $20.00 and set a “hold” rating for the company in a report on Wednesday, December 18th. UBS Group lifted their target price on AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. JPMorgan Chase & Co. cut their target price on AnaptysBio from $66.00 to $36.00 and set an “overweight” rating on the stock in a research report on Thursday, December 19th. Wells Fargo & Company dropped their price target on AnaptysBio from $56.00 to $40.00 and set an “overweight” rating on the stock in a research note on Thursday, December 12th. Finally, Wedbush reaffirmed an “outperform” rating and set a $40.00 price objective (down from $42.00) on shares of AnaptysBio in a research note on Wednesday, December 11th. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, AnaptysBio currently has an average rating of “Moderate Buy” and an average price target of $41.45.

Insider Transactions at AnaptysBio

In other AnaptysBio news, Director Ecor1 Capital, Llc purchased 6,646 shares of the company’s stock in a transaction dated Thursday, January 2nd. The shares were bought at an average price of $12.95 per share, for a total transaction of $86,065.70. Following the purchase, the director now directly owns 7,880,094 shares in the company, valued at $102,047,217.30. This trade represents a 0.08 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 33.70% of the company’s stock.

AnaptysBio Stock Performance

Shares of ANAB opened at $16.85 on Friday. AnaptysBio, Inc. has a 52 week low of $12.51 and a 52 week high of $41.31. The company has a market capitalization of $512.75 million, a PE ratio of -2.77 and a beta of -0.02. The company’s 50 day moving average price is $17.67 and its 200 day moving average price is $27.52.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.72) by $0.58. The business had revenue of $30.02 million for the quarter, compared to the consensus estimate of $7.92 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. On average, equities analysts forecast that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.